Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2021 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study.
Gridelli C, Manzione L, Perrone F, Veltri E, Cioffi R, Caprio MG, Frontini L, Rossi A, Barletta E, Barzelloni ML, Bilancia D, Gallo C. Gridelli C, et al. Br J Cancer. 2001 Jan 5;84(1):38-41. doi: 10.1054/bjoc.2000.1541. Br J Cancer. 2001. PMID: 11139310 Free PMC article. Clinical Trial.
A multicentre phase 2 trial (single-stage design) was undertaken to test the efficacy and toxicity of carboplatin (AUC 6 according to Calvert) plus paclitaxel (175 mg/m(2)3-h infusion) every 4 weeks in the first line treatment of patients affect …
A multicentre phase 2 trial (single-stage design) was undertaken to test the efficacy and toxicity of carboplatin (AUC …
Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L).
Miyawaki T, Kenmotsu H, Harada H, Ohde Y, Chiba Y, Haratani K, Okimoto T, Sakamoto T, Wakuda K, Ito K, Uemura T, Sakata S, Kogure Y, Nishimura Y, Nakagawa K, Yamamoto N. Miyawaki T, et al. BMC Cancer. 2021 Oct 18;21(1):1121. doi: 10.1186/s12885-021-08851-z. BMC Cancer. 2021. PMID: 34663250 Free PMC article.
BACKGROUND: Synchronous oligometastatic non-small cell lung cancer (NSCLC) is generally characterised by the limited number of metastases at the time of diagnosis. ...If the primary endpoint of this study is met, extensive phase II …
BACKGROUND: Synchronous oligometastatic non-small cell lung cancer (NSCLC) is generally characterised by the lim …